Kura Oncology, Inc. is a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and hematologic cancers. Kura’s pipeline consists of two wholly-owned small molecule drug candidates that target cancer signaling pathways. Kura’s most advanced drug candidate, tipifarnib, is a potent, selective and orally bioavailable farnesyl transferase inhibitor. Kura’s second candidate, KO-539, is a potentially first-in-class, potent and selective inhibitor of the menin-MLL protein-protein interaction.